


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:09Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406563" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406563</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcph</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Public Health</journal-id><journal-id journal-id-type="iso-abbrev">BMC Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">63</journal-id><journal-id journal-id-type="pmc-domain">bmcph</journal-id><journal-title-group><journal-title>BMC Public Health</journal-title></journal-title-group><issn pub-type="epub">1471-2458</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406563</article-id><article-id pub-id-type="pmcid-ver">PMC12406563.1</article-id><article-id pub-id-type="pmcaid">12406563</article-id><article-id pub-id-type="pmcaiid">12406563</article-id><article-id pub-id-type="pmid">40898106</article-id><article-id pub-id-type="doi">10.1186/s12889-025-24320-9</article-id><article-id pub-id-type="publisher-id">24320</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Nonlinear associations between the aggregate index of systemic inflammation and cardiovascular disease in adults: evidence from NHANES 2011&#8211;2020</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="R">Run</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="R">Ruoling</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tao</surname><given-names initials="W">Weijun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cheng</surname><given-names initials="X">Xiaobing</given-names></name><address><email>doccxb@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05mfr7w08</institution-id><institution-id institution-id-type="GRID">grid.459597.3</institution-id><institution>Department of Cardiology, </institution><institution>The Third People&#8217;s Hospital of Hefei (The Third Clinical College of Anhui Medical University), </institution></institution-wrap>Hefei, Anhui China </aff><aff id="Aff2"><label>2</label>Department of Endocrinology, The Second People&#8217;s Hospital of Wuhu, Wuhu, Anhui China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478168</issue-id><elocation-id>3031</elocation-id><history><date date-type="received"><day>19</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>6</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12889_2025_Article_24320.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Although the connection between inflammation and cardiovascular disease (CVD) is well-documented, the association involving the aggregate index of systemic inflammation (AISI)&#8212;a distinctive indicator derived from this formula (neutrophil count &#215; monocyte count &#215; platelet count)/lymphocyte count&#8212;has not been extensively explored. Addressing this research gap, our study leveraged the National Health and Nutrition Examination Survey (NHANES) database for investigating a correlation among AISI and CVD among adults in U.S. This investigation provides new insights into the inflammatory mechanisms underlying cardiovascular conditions and may have implications for preventive and therapeutic strategies in cardiovascular health.</p></sec><sec><title>Methods</title><p id="Par2">Our study included 23,472 adults from the 2011&#8211;2020 NHANES database. The relationship between AISI and CVD was examined using weighted generalized linear models, subgroup analyses, and threshold effects to estimate effect sizes and saturation effects. Nonlinear relationships between the AISI and CVD were further elucidated through smoothed curve analyses.</p></sec><sec><title>Results</title><p id="Par3">The prevalence of CVD increases with AISI(<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Within weighted generalized linear models, individuals within Quartile 4 [OR&#8201;=&#8201;1.27, 95%CI (1.00, 1.61)] exhibited a favorable correlation with CVD prevalence, in contrast to the figures observed during Quartile 1. Notably, this correlation was consistent across various subgroups, indicating its independence from factors such as age, ethnicity, smoking, hyperlipidemia, hypertension, and diabetes mellitus (<italic toggle="yes">P</italic> for interaction&#8201;&gt;&#8201;0.05). Additionally, using threshold effect analysis, we identified a nonlinear relationship across AISI and CVD, with a critical inflection point observed at an index value of 467. Above this threshold, every increment of 100 units within AISI was linked to a 3% elevated CVD prevalence [OR&#8201;=&#8201;1.03, 95%CI (1.00, 1.07)].</p></sec><sec><title>Conclusion</title><p id="Par4">Our work substantiates robust evidence for a important positive correlation between AISI and CVD. However, it also highlights the importance of conducting additional prospective research to comprehensively explore the function of AISI in etiology and advancement of CVD.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Aggregate index of systemic inflammation</kwd><kwd>Inflammation</kwd><kwd>Cardiovascular disease</kwd><kwd>NHANES</kwd><kwd>Cross-sectional study</kwd></kwd-group><funding-group><award-group><funding-source><institution>2023 Hefei Third People&#8217;s Hospital Institutional-Level Scientific Research Project</institution></funding-source><award-id>SYKY202303</award-id><award-id>SYKY202303</award-id><award-id>SYKY202303</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Run</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Weijun</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Xiaobing</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>The Sixth Batch of Renowned Physician Studios in Hefei City</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>2024 Bengbu Medical College Science and Technology Project</institution></funding-source><award-id>2024byzd367</award-id><award-id>2024byzd367</award-id><award-id>2024byzd367</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Run</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Weijun</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Xiaobing</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par20">Cardiovascular disease (CVD) stands as the primary cause of morbidity and mortality among adults globally [<xref ref-type="bibr" rid="CR1">1</xref>]. In 2020, an alarming 928,741 Americans succumbed to CVD, registering the greatest annual fatality count in recent history [<xref ref-type="bibr" rid="CR2">2</xref>]. The annual financial burden for CVD in the United States is staggering, amounting to hundreds of billions of dollars [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par21">For many years, inflammation has been recognized as a pivotal factor in causing atherosclerosis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Both systemic and localized inflammation play pivotal roles in CVD progression. This process exacerbates endothelial dysfunction, facilitates the generation and progression of atherosclerotic plaques, and elevates the likelihood of plaque rupture, thereby elevating a susceptibility to CVD. Both systemic and localized inflammation play crucial roles in the progression of CVD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The onset and progression of atherosclerosis within vascular endothelium, culminating in plaque formation and eventual rupture, is a multifaceted process. This process intricately engages not only innate and adaptive immune systems, but also critical involvement of hematopoietic organs like the bone marrow and spleen. This comprehensive approach highlights the interconnected nature of atherosclerosis, linking localized endothelial changes to broader systemic immune responses [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par22">Systemic inflammation is quantified via biochemical or hematological tests. The aggregate index of systemic inflammation (AISI), an innovative marker, facilitates this measurement economically and conveniently using neutrophils, lymphocytes, monocytes, and platelets. AISI integrates multiple cellular components of the inflammatory response, potentially offering a more holistic representation of immune activation. Recent studies have demonstrated the efficiency of AISI in predicting ICU admission rates and mortality in COVID-19 patients [<xref ref-type="bibr" rid="CR9">9</xref>], as well as cardiovascular mortality in hypertensive adults [<xref ref-type="bibr" rid="CR10">10</xref>]. Furthermore, AISI, along with the system inflammation response index (SIRI), has proven to be a crucial prognostic indicator for key adverse cardiovascular events in individuals having moderate coronary artery stenosis [<xref ref-type="bibr" rid="CR11">11</xref>]. Additionally, in follow-up studies of total knee arthroplasty patients, AISI, SIRI, and systemic immune inflammation index (SII) are identified as independent predictors for deep vein thrombosis&#8217; formation [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par23">However, the clinical adoption of AISI remains limited due to unresolved challenges: its dependence on routine blood counts may introduce variability due to pre-analytical factors, including diurnal fluctuations, and acute infections; the biological interpretation of AISI as a multiplicative index&#8212;rather than a simple additive score&#8212;requires further mechanistic validation; and its prognostic value in CVD remains underexplored. Despite the emergence of the AISI as a novel biomarker, its correlation with CVD remains uncharted territory. To address this gap in understanding, our research harnesses an extensive NHANES database.</p><p id="Par24">Therefore, our objective is to delve into this correlation among AISI and CVD within the broader spectrum of adult individuals, thereby contributing new insights into this critical health concern.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par25">The NHANES is structured to evaluate the health and nutritional status of both adults and children in U.S. by conducting surveys and comprehensive physical assessments. The research methodologies employed in NHANES were cleared by the National Center for Health Statistics (NCHS) Research Ethics Review Board, and all participants within this survey have granted written informed consent.</p><p id="Par26">This study included 45,462 participants from 2011 to 2020 NHANES database, excluding 19,182 individuals under the age of 20, 2808 individuals lacking neutrophils, lymphocytes, monocytes, platelets, and other covariates, and individuals lacking questionnaires for the diagnosis of CVD. This included 23,472 participants enrolled within this research. A flowchart illustrating this study participants is presented within Fig. <xref rid="Fig1" ref-type="fig">1</xref>, which also describes this systematic participant choice procedure.</p><p id="Par27">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The process flow diagram for the systematic selection method</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12889_2025_24320_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Definition of aggregate index of systemic inflammation and cardiovascular disease</title><p id="Par28">AISI was the exposure variable in this research. Complete blood count (CBC) parameters, including lymphocyte, monocyte, neutrophil, and platelet counts, were measured in the NHANES mobile examination centers (MECs) using the Beckman Coulter DxH 800 automated hematology analyzer. The AISI calculation is obtained by multiplying the neutrophil, platelet, and monocyte counts, followed by dividing this resultant product, through a lymphocyte ratio [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par29">Within this research, definition of CVD was based on survey questionnaire responses. Participants were classified as having CVD if they reported any of the following conditions: angina, myocardial infarction (MI), stroke, congestive heart failure (CHF), or coronary heart disease (CHD). A favorable answer to any of these inquiries was deemed to signify the presence of CVD.</p></sec><sec id="Sec5"><title>Covariates</title><p id="Par30">Educational attainment was classified into three distinct tiers: below high school level, high school level or its equivalent, and those with a college degree or higher. PIR is segmented into three distinct categories, low-income (PIR&#8201;&lt;&#8201;1.3), middle-income (&#8805;&#8201;1.3 and &lt;&#8201;3.5), and high-income (PIR&#8201;&#8805;&#8201;3.5) [<xref ref-type="bibr" rid="CR15">15</xref>]. Additionally, BMI was classified into three categories: normal (&lt;&#8201;25 kg/m<sup>2</sup>), overweight (25 kg/m<sup>2</sup>&#8722;30 kg/m<sup>2</sup>), and obese(&gt;&#8201;30 kg/m<sup>2</sup>). Men were considered to engage in excessive alcohol consumption if they consumed more than four drinks daily, while for women, the threshold was set at three sips per day. For women, two drinks per day and for males, three drinks per day was considered moderate alcohol consumption. Additional alcohol intake was considered minimal [<xref ref-type="bibr" rid="CR16">16</xref>]. Individuals were classified as smokers if they had consumed more than one hundred cigarettes in a year [<xref ref-type="bibr" rid="CR17">17</xref>] and defined hyperlipidemia as a total cholesterol level&#8201;&#8805;&#8201;200 mg/dL, triglycerides level&#8201;&#8805;&#8201;150 mg/dL, high-density lipoprotein level&#8201;&#8804;&#8201;40 mg/dL in men and &#8804;&#8201;50 mg/dL in women, or &#8805;&#8201;130 mg/dL of low-density lipoprotein [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Hypertension was identified based on any of the following criteria: utilize of antihypertensive medications, systolic blood pressure&#8201;&#8805;&#8201;140 mmHg, diastolic blood pressure&#8201;&#8805;&#8201;90 mmHg, or a previous instance of hypertension as indicated in the questionnaire. For this investigation, comprehensive clinical parameters and detailed laboratory findings were meticulously gathered. Diabetes was diagnosed based on a history of the disease, fasting plasma glucose levels&#8201;&#8805;&#8201;126 mg/dL, 2-h postprandial blood glucose levels&#8201;&#8805;&#8201;200 mg/dL, HbA1c values&#8201;&#8805;&#8201;6.5%, or employ of insulin or hypoglycemic medicines were employed for diagnose diabetes.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par31">The mean and standard error (SE) were used to represent continuous variables, while the number of individuals and portion were used for describing categorical variables. For ensuring reliable and typical statistical analysis, we followed the NHANES standards for complicated sample weight calculations because of the database&#8217;s intricate probability-stratified sampling architecture. For baseline characteristic analysis, participants were categorized into quartiles according to this weighted AISI. Analyzing the nonlinear relationship between CVD and AISI with weighted generalized linear models. Basic and unadjusted, Model 1 was followed by Model 2 which included age and racial adjustments, and Model 3 which extended these controls to include diabetes, hypertension, smoking status, and hyperlipidemia. Utilizing restricted cubic spline curves, we delved into the exploration of nonlinear associations. To determine the crucial turning points in this association, we conducted a threshold effect analysis. A segmented regression technique was used to investigate threshold effects, identifying the ideal inflection point at which the relationship pattern undergoes a substantial shift using piecewise regression models. The piecewise regression model was compared to a traditional linear model using the log-likelihood ratio test in order to verify statistical significance.</p><p id="Par32">For assessing the strength of a relationship among AISI and CVD, weighted subgroup analyses were undertaken. To validate our results, we conducted an unweighted logistic regression analysis. All statistical computations were executed with R studio (edition 4.2.2) and EmpowerStats (version 4.1).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Baseline characteristics of individuals</title><p id="Par33">A total of 23,472 participants, boasting average age of 49.69&#8201;&#177;&#8201;17.55 years, were included, 48.24% of them were male and 51.76% were female, the total number of CVD was 2550 and the overall prevalence was 10.86%.</p><p id="Par34">According to Table <xref rid="Tab1" ref-type="table">1</xref>, grouped being contingent on AISI quartiles, Quartile 1 ranged from 0 to 150.97, Quartile 2 ranged from 150.99 to 237.69, Quartile 3 ranged from 237.71 to 374.19, and Quartile 4 ranged from 374.21 to 7876.44. The prevalence of CVD increased simultaneously with the AISI quartiles, with this difference being statistically significant (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01). Notably, substantial statistical disparities were detected among the four quartiles with respect to age, ethnicity, level of education, BMI, PIR, smoking, level of alcohol consumption, hyperlipidemia, hypertension, and diabete mellitus (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). However, there was no significant discrepancy in gender distribution (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05).</p><p id="Par35">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Initial characteristics of the research individuals according to AISI quartile categories</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1"/><th align="left" colspan="4" rowspan="1">AISI Quartile</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;5869</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;5867</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;5868</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;5868</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">Quartile 1</th><th align="left" colspan="1" rowspan="1">Quartile 2</th><th align="left" colspan="1" rowspan="1">Quartile 3</th><th align="left" colspan="1" rowspan="1">Quartile 4</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, Mean (S.E)</td><td align="left" colspan="1" rowspan="1">48.7 (17.0)</td><td align="left" colspan="1" rowspan="1">49.2 (17.1)</td><td align="left" colspan="1" rowspan="1">49.5 (17.5)</td><td align="left" colspan="1" rowspan="1">51.4 (18.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001***</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td align="left" colspan="1" rowspan="1">2789 (47.5)</td><td align="left" colspan="1" rowspan="1">2852 (48.6)</td><td align="left" colspan="1" rowspan="1">2792 (47.6)</td><td align="left" colspan="1" rowspan="1">2889 (49.2)</td><td align="left" colspan="1" rowspan="1">0.64</td></tr><tr><td align="left" colspan="5" rowspan="1">Race, n (%)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mexican American</td><td align="left" colspan="1" rowspan="1">666 (11.3)</td><td align="left" colspan="1" rowspan="1">805 (13.7)</td><td align="left" colspan="1" rowspan="1">833 (14.2)</td><td align="left" colspan="1" rowspan="1">763 (13.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Hispanic</td><td align="left" colspan="1" rowspan="1">541 (9.2)</td><td align="left" colspan="1" rowspan="1">669 (11.4)</td><td align="left" colspan="1" rowspan="1">663 (11.3)</td><td align="left" colspan="1" rowspan="1">637 (10.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">1432 (24.4)</td><td align="left" colspan="1" rowspan="1">2084 (35.5)</td><td align="left" colspan="1" rowspan="1">2404 (41.0)</td><td align="left" colspan="1" rowspan="1">2772 (47.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">2088 (35.6)</td><td align="left" colspan="1" rowspan="1">1341 (22.9)</td><td align="left" colspan="1" rowspan="1">1076 (18.3)</td><td align="left" colspan="1" rowspan="1">968 (16.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Race</td><td align="left" colspan="1" rowspan="1">1142 (19.5)</td><td align="left" colspan="1" rowspan="1">968 (16.5)</td><td align="left" colspan="1" rowspan="1">892 (15.2)</td><td align="left" colspan="1" rowspan="1">728 (12.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Education, n (%)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Less than high school</td><td align="left" colspan="1" rowspan="1">1206 (20.5)</td><td align="left" colspan="1" rowspan="1">1277 (21.8)</td><td align="left" colspan="1" rowspan="1">1233 (21.0)</td><td align="left" colspan="1" rowspan="1">1273 (21.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;High school or equivalent</td><td align="left" colspan="1" rowspan="1">1289 (22.0)</td><td align="left" colspan="1" rowspan="1">1243 (21.2)</td><td align="left" colspan="1" rowspan="1">1318 (22.5)</td><td align="left" colspan="1" rowspan="1">1436 (24.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;College or above</td><td align="left" colspan="1" rowspan="1">3374 (57.5)</td><td align="left" colspan="1" rowspan="1">3347 (57.0)</td><td align="left" colspan="1" rowspan="1">3317 (56.5)</td><td align="left" colspan="1" rowspan="1">3159 (53.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">BMI, n (%)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;&#8201;25.0</td><td align="left" colspan="1" rowspan="1">1973 (33.6)</td><td align="left" colspan="1" rowspan="1">1702 (29.0)</td><td align="left" colspan="1" rowspan="1">1496 (25.5)</td><td align="left" colspan="1" rowspan="1">1333 (22.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;25.0-29.9</td><td align="left" colspan="1" rowspan="1">2000 (34.1)</td><td align="left" colspan="1" rowspan="1">1996 (34.0)</td><td align="left" colspan="1" rowspan="1">1903 (32.4)</td><td align="left" colspan="1" rowspan="1">1858 (31.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8805;&#8201;30.0</td><td align="left" colspan="1" rowspan="1">1896 (32.3)</td><td align="left" colspan="1" rowspan="1">2169 (37.0)</td><td align="left" colspan="1" rowspan="1">2469 (42.1)</td><td align="left" colspan="1" rowspan="1">2677 (45.6)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">PIR</td><td align="left" colspan="1" rowspan="1">0.02*</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;&#8201;1.3</td><td align="left" colspan="1" rowspan="1">1660 (28.3)</td><td align="left" colspan="1" rowspan="1">1623 (27.7)</td><td align="left" colspan="1" rowspan="1">1689 (28.8)</td><td align="left" colspan="1" rowspan="1">1755 (29.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;1.3&#8211;3.4</td><td align="left" colspan="1" rowspan="1">2502 (42.6)</td><td align="left" colspan="1" rowspan="1">2538 (43.3)</td><td align="left" colspan="1" rowspan="1">2570 (43.8)</td><td align="left" colspan="1" rowspan="1">2625 (44.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8805;&#8201;3.5</td><td align="left" colspan="1" rowspan="1">1707 (29.1)</td><td align="left" colspan="1" rowspan="1">1706 (29.1)</td><td align="left" colspan="1" rowspan="1">1609 (27.4)</td><td align="left" colspan="1" rowspan="1">1488 (25.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking, n (%)</td><td align="left" colspan="1" rowspan="1">2176 (37.1)</td><td align="left" colspan="1" rowspan="1">2332 (39.7)</td><td align="left" colspan="1" rowspan="1">2551 (43.5)</td><td align="left" colspan="1" rowspan="1">2901 (49.4)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="5" rowspan="1">Drinking, n (%)</td><td align="left" colspan="1" rowspan="1"><p>0.002</p><p>**</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Light drinking</td><td align="left" colspan="1" rowspan="1">2841 (48.4)</td><td align="left" colspan="1" rowspan="1">2759 (47.0)</td><td align="left" colspan="1" rowspan="1">2700 (46.0)</td><td align="left" colspan="1" rowspan="1">2707 (46.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Moderate drinking</td><td align="left" colspan="1" rowspan="1">2175 (37.1)</td><td align="left" colspan="1" rowspan="1">2131 (36.3)</td><td align="left" colspan="1" rowspan="1">2122 (36.2)</td><td align="left" colspan="1" rowspan="1">2099 (35.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heavy drinking</td><td align="left" colspan="1" rowspan="1">853 (14.5)</td><td align="left" colspan="1" rowspan="1">977 (16.7)</td><td align="left" colspan="1" rowspan="1">1046 (17.8)</td><td align="left" colspan="1" rowspan="1">1062 (18.1)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia, n (%)</td><td align="left" colspan="1" rowspan="1">3208 (54.7)</td><td align="left" colspan="1" rowspan="1">3408 (58.1)</td><td align="left" colspan="1" rowspan="1">3550 (60.5)</td><td align="left" colspan="1" rowspan="1">3563 (60.7)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">2338 (39.8)</td><td align="left" colspan="1" rowspan="1">2400 (40.9)</td><td align="left" colspan="1" rowspan="1">2548 (43.4)</td><td align="left" colspan="1" rowspan="1">3015 (51.4)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes, n (%)</td><td align="left" colspan="1" rowspan="1">946 (16.1)</td><td align="left" colspan="1" rowspan="1">1029 (17.5)</td><td align="left" colspan="1" rowspan="1">1143 (19.5)</td><td align="left" colspan="1" rowspan="1">1366 (23.3)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Cardiovascular disease, n (%)</td><td align="left" colspan="1" rowspan="1">495 (8.4)</td><td align="left" colspan="1" rowspan="1">533 (9.1)</td><td align="left" colspan="1" rowspan="1">640 (10.9)</td><td align="left" colspan="1" rowspan="1">882 (15.0)</td><td align="left" colspan="1" rowspan="1"><p>&lt;&#8201;0.001</p><p>***</p></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">BMI</italic> Body mass index, <italic toggle="yes">PIR</italic> Poverty income ratio, <italic toggle="yes">SE</italic> Standard error</p><p>*** <italic toggle="yes">P</italic> value&#8201;&lt;&#8201;0.001, ** <italic toggle="yes">P</italic> value&#8201;&lt;&#8201;0.01, * <italic toggle="yes">P</italic> value&#8201;&lt;&#8201;0.05</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Association of the AISI with CVD</title><p id="Par36">Table <xref rid="Tab2" ref-type="table">2</xref> illustrates the direct relationship between AISI and CVD prevalence. When considering AISI as continuous variables, an impact associated with a one-unit change is relatively modest; therefore, we report the odds ratio per 100-unit increase in AISI to better illustrate the magnitude of the association. In the unadjusted [1.08(1.06, 1.10)], partially adjusted [1.06(1.04, 1.08)], and fully adjusted models [1.03(1.01, 1.05)], a statistically significant positive relationship was discovered between AISI and CVD prevalence (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Across the unadjusted, partially adjusted, and fully adjusted models, Quartile 4 individuals showed a greater prevalence than Quartile 1 when examined using AISI quartiles (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Specifically, within model 3, CVD prevalence within Quartile 4 was 27.0% outstanding compared to Quartile 1[1.27(1.00, 1.61)].</p><p id="Par37">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The connection between weighted AISI and cardiovascular disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th></tr><tr><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AISI</td><td align="left" colspan="1" rowspan="1"><p>1.08(1.06, 1.10)</p><p>&lt;&#8201;0.001***</p></td><td align="left" colspan="1" rowspan="1"><p>1.06(1.04, 1.08)</p><p>&lt;&#8201;0.001***</p></td><td align="left" colspan="1" rowspan="1"><p>1.03(1.01, 1.05)</p><p>0.002**</p></td></tr><tr><td align="left" colspan="1" rowspan="1">AISI Quartiles</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Quartile 1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">Quartile 2</td><td align="left" colspan="1" rowspan="1"><p>1.21(1.03, 1.42)</p><p>0.02</p></td><td align="left" colspan="1" rowspan="1"><p>1.21(1.00, 1.45)</p><p>0.05</p></td><td align="left" colspan="1" rowspan="1"><p>1.13(0.93, 1.36)</p><p>0.21</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Quartile 3</td><td align="left" colspan="1" rowspan="1"><p>1.37(1.133,1.65)</p><p>0.002</p></td><td align="left" colspan="1" rowspan="1"><p>1.29(1.06, 1.57)</p><p>0.01</p></td><td align="left" colspan="1" rowspan="1"><p>1.12(0.92, 1.36)</p><p>0.25</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Quartile 4</td><td align="left" colspan="1" rowspan="1"><p>1.89(1.55, 2.31)</p><p>&lt;&#8201;0.001</p></td><td align="left" colspan="1" rowspan="1"><p>1.60(1.28, 2.01)</p><p>&lt;&#8201;0.001</p></td><td align="left" colspan="1" rowspan="1"><p>1.27(1.00, 1.61)</p><p>0.05</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> for trend</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.09</td></tr></tbody></table><table-wrap-foot><p>Model 1 was unadjusted for variables, model 2 was adjusted for age, and race, and model 3 was adjusted for the above factors smoking, hyperlipidemia, diabetes, and hypertension</p><p>Odds ratios are presented per 100-unit increase in the AISI</p></table-wrap-foot></table-wrap>
</p><p id="Par38">In Fig. <xref rid="Fig2" ref-type="fig">2</xref>, an inflection point was observed under an AISI score of 467. Below this threshold, the association between AISI and CVD prevalence was not statistically significant (OR per 100-unit increase&#8201;=&#8201;1.06, 95% CI: 0.97&#8211;1.16), whereas above 467, an increase of 100 units in AISI was linked to a 3% rise CVD prevalence (OR&#8201;=&#8201;1.03, 95% CI: 1.00&#8211;1.07). (Table <xref rid="Tab3" ref-type="table">3</xref>)</p><p id="Par39">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The connection between AISI and cardiovascular disease</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12889_2025_24320_Fig2_HTML.jpg"/></fig>
</p><p id="Par40">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Linear regression models are applied to examine the threshold impact of AISI on cardiovascular disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">AISI</th><th align="left" colspan="1" rowspan="1">Adjusted OR 95%CI, <italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Inflection point</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AISI&#8201;&lt;&#8201;467</td><td align="left" colspan="1" rowspan="1">1.06(0.97, 1.16) <italic toggle="yes">P</italic>&#8201;=&#8201;0.19</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AISI&#8201;&#8805;&#8201;467</td><td align="left" colspan="1" rowspan="1">1.03(1.00, 1.07) <italic toggle="yes">P&#8201;=</italic>&#8201;0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Log likelihood ratio</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>&#8201;=&#8201;0.005</td></tr></tbody></table><table-wrap-foot><p>Odds ratios are presented per 100-unit increase in the AISI</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Subgroup investigation of the correlation between the AISI and CVD</title><p id="Par41">Subgroup analyses were conducted to explore the association between the AISI and CVD across different demographic and clinical characteristics. Overall, a 100-unit increase in AISI was significantly associated with a higher prevalence of CVD in most subgroups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). This positive correlation remained unaffected by factors, like age, race, smoking, hyperlipidemia, hypertension, or diabetes, as indicated by P-values greater than 0.05 (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par42">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Subgroup analysis of the connection between AISI and cardiovascular disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">AISI</th><th align="left" colspan="1" rowspan="1">OR (95%CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> Value</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> for interaction</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8805;&#8201;50</td><td align="left" colspan="1" rowspan="1">1.05 (1.02, 1.07)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&lt;&#8201;50</td><td align="left" colspan="1" rowspan="1">1.05 (1.00, 1.09)</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Race</td><td align="left" colspan="1" rowspan="1">0.78</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mexican American</td><td align="left" colspan="1" rowspan="1">1.05 (0.99, 1.11)</td><td align="left" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Hispanic</td><td align="left" colspan="1" rowspan="1">1.05 (0.97, 1.14)</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">1.03 (1.00, 1.05)</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">1.05 (1.01, 1.10)</td><td align="left" colspan="1" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Race</td><td align="left" colspan="1" rowspan="1">1.04 (0.99, 1.09)</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Smoking</td><td align="left" colspan="1" rowspan="1">0.051</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">1.02 (1.00, 1.04)</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">1.06 (1.03, 1.09)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">0.63</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">1.03 (1.00, 1.06)</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">1.04 (1.01, 1.06)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">1.03 (1.01, 1.05)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">1.03 (0.98, 1.09)</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Diabetes</td><td align="left" colspan="1" rowspan="1">0.15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">1.01 (0.99, 1.04)</td><td align="left" colspan="1" rowspan="1">0.35</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">1.04 (1.02, 1.07)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Odds ratios are presented per 100-unit increase in the AISI</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Sensitivity analysis</title><p id="Par43">The sensitivity analysis using unweighted logistic models in Table <xref rid="Tab5" ref-type="table">5</xref> shows that AISI and the prevalence of CVD are positively correlated in all models (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). These conclusions are supported by the results in Table <xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par44">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>The connection between unweighted AISI and cardiovascular disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">OR (95CI%) <italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AISI</td><td align="left" colspan="1" rowspan="1"> 1.08(1.066, 1.092)&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"><p>1.06(1.04, 1.07)</p><p>&lt;&#8201;0.001</p></td><td align="left" colspan="1" rowspan="1"><p>1.04(1.02, 1.05)</p><p>&lt;&#8201;0.001</p></td></tr><tr><td align="left" colspan="4" rowspan="1">AISI Quartiles</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Quartile 1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Quartile 2</td><td align="left" colspan="1" rowspan="1"><p>1.08(0.96, 1.23)</p><p>0.22</p></td><td align="left" colspan="1" rowspan="1"><p>1.07 (0.93, 1.22)</p><p>0.36</p></td><td align="left" colspan="1" rowspan="1"><p>1.02(0.88, 1.17)</p><p>0.82</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Quartile 3</td><td align="left" colspan="1" rowspan="1">1.33 (1.17, 1.50)&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">1.29(1.13, 1.50)&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"><p>1.16(1.01, 1.33)</p><p>0.03</p></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Quartile 4</td><td align="left" colspan="1" rowspan="1">1.92 (1.71, 2.16)&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"><p>1.64(1.44, 1.86)</p><p>&lt;&#8201;0.001</p></td><td align="left" colspan="1" rowspan="1"><p>1.35(1.18, 1.54)</p><p>&lt;&#8201;0.001</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">&#8195;P</italic> for trend</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Model 1 was unadjusted for variables, model 2 was adjusted for age and race, and model 3 was adjusted for the above factors smoking, hyperlipidemia, diabetes, and hypertension</p><p>Odds ratios are presented per 100-unit increase in the AISI</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par45">This comprehensive cross-sectional analysis included 23,472 participants sourced 2011&#8211;2020 NHANES database. Importantly, the prevalence of CVD was significantly higher when AISI was treated as a categorical variable. Smoothed curve analysis unveiled a nonlinear relationship between AISI and CVD, with an inflection point at 467. Below this value, the weaker association suggests that low-grade inflammation exerts a limited impact on cardiovascular risk, potentially due to physiological adaptation or measurement insensitivity. In contrast, the stronger association above 467 implies that exceeding this threshold may overwhelm endogenous anti-inflammatory mechanisms, thereby accelerating atherosclerosis or plaque destabilization. Subgroup and interaction analysis further demonstrated that this connection remained valid for variables such as age, race, smoking, hyperlipidemia, hypertension, and diabetes status.</p><p id="Par46">To our understanding, our study represents the inaugural exploration into the link among CVD and AISI. A thorough systematic review and meta-analysis, integrating data from 13 studies, has uncovered a notable correlation between initial AISI levels and the heightened risk of severe illness or mortality upon discharge among patients hospitalized with COVID-19. Furthermore, baseline AISI effectively distinguished between disease severity and survival outcomes [<xref ref-type="bibr" rid="CR20">20</xref>]. Retrospective studies also indicated that AISI predicted mortality among COVID-19 patients suffering from chronic renal disease, facilitating early identification of those at heightened risk for adverse outcome [<xref ref-type="bibr" rid="CR21">21</xref>]. Research by Zinellu et al. further established AISI as a standalone risk factor for individuals having idiopathic pulmonary fibrosis [<xref ref-type="bibr" rid="CR22">22</xref>]. In contrast, our study found that AISI, a composite marker of systemic chronic inflammation derived from peripheral blood cell profiles, demonstrated a positive correlation with CVD across all three of our study models. Specifically, the inflection points at an AISI value of 467 suggest a nonlinear relationship between systemic inflammation and CVD. Below this threshold, the association was weaker, possibly indicating a saturation effect of low-grade inflammation on cardiovascular risk. Above the inflection point, the stronger association may reflect a critical level of systemic inflammation that significantly contributes to CVD pathogenesis. This finding highlights the potential utility of AISI as a biomarker for identifying individuals at higher risk of CVD, particularly those with elevated systemic inflammation. And our study extends Xiu et al. work by investigating the broader link among AISI and CVD in general population, beyond hypertension [<xref ref-type="bibr" rid="CR10">10</xref>]. We further innovated by analyzing nonlinear relationships and threshold effects, providing new insights into AISI&#8217;s potential as a comprehensive cardiovascular risk predictor.</p><p id="Par47">Neutrophils, the most abundant leukocyte subtype, are increasingly recognized for their role in major adverse cardiovascular events [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref>]. These cells accumulate near vulnerable atherosclerotic plaques, particularly when endothelial integrity is compromised, and lipid deposition occurs. Their contribution to plaque formation and destabilization is substantial, primarily through the release of myeloperoxidase, NADPH oxidase, and lipoxygenase, which collectively exacerbate atherosclerosis [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The role of monocytes in the progression of atherosclerosis is also significant. Upon differentiating into macrophages, monocytes secrete various inflammatory mediators and enzymes, creating an environment that promotes atherosclerotic progression [<xref ref-type="bibr" rid="CR28">28</xref>]. Lymphocytes, including B and T cells, play different roles in this context. B lymphocytes appear to inhibit atherosclerosis progression, while T lymphocytes are critical in advancing the disease, thereby substantially influencing the atherosclerotic process [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Beyond their primary role in hemostasis, platelets are also pivotal in cardiovascular pathology. Their interaction with inflammatory cells facilitates thrombogenesis, a crucial precursor to cardiovascular events and strokes [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The complex mechanisms linking CVD and inflammation underscore the dual role of inflammation as both a cause and a risk factor, as well as an indicator of poor outcomes [<xref ref-type="bibr" rid="CR33">33</xref>]. Consequently, over the past decades, numerous inflammatory markers have been explored. Identifying appropriate biomarkers not only helps control inflammation but also enables monitoring of therapeutic efficacy and management of disease progression in CVD. Unlike evaluating individual inflammatory markers in isolation, our application of AISI offers several advantages. By integrating multiple immune cells counts, AISI provides a comprehensive assessment of an individual&#8217;s overall inflammatory status. This unified approach not only facilitates risk stratification by consolidating diverse immune parameters but also captures the complex interactions among these cells that drive the inflammatory processes underlying CVD.</p><p id="Par48">Our work boasts several notable advantages, notably its substantial sample size and diverse, multiethnic dataset from NHANES, which together enhance the reliability and robustness of our findings. Additionally, our analytical model carefully controlled for a range of confounding covariates. In our subgroup analyses, we sought to explore this correlation among AISI and CVD across different population groups, thereby increasing the generalizability of our results. However, our study is accompanied by several significant constraints. Firstly, being a cross-sectional study, it is impractical for us to establish a definitive causal connection between AISI and CVD. Secondly, despite our efforts to adjust for numerous covariates, the potential influence of unaccounted confounders remains a concern. For instance, factors such as the use of antibiotics or steroids may have influenced our results, but due to the lack of this data in NHANES, we were unable to analyze their effects. Thirdly, the diagnosis of CVD is largely based on self-reported data and does not routinely include imaging or advanced diagnostic testing. Given these limitations, there is a strong need for larger, multicenter, prospective cohort studies. Such studies would be valuable in further exploring the relationship between AISI and CVD, thereby enhancing our understanding in this critical area of cardiovascular research.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par49">To summarize, our research identifies a significant positive correlation between AISI and CVD. As an innovative systemic inflammatory marker, AISI possesses the capability to act as an affordable and practical means for early detection of CVD and assessing the efficacy of CVD treatments.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AISI</term><def><p id="Par5">Aggregate index of systemic inflammation</p></def></def-item><def-item><term>PIR</term><def><p id="Par6">Poverty income ratio</p></def></def-item><def-item><term>NHANES</term><def><p id="Par7">National Health and Nutrition Examination Survey</p></def></def-item><def-item><term>95% CI</term><def><p id="Par8">95% confidence interval</p></def></def-item><def-item><term>SE</term><def><p id="Par9">Standard error</p></def></def-item><def-item><term>CVD</term><def><p id="Par10">Cardiovascular disease</p></def></def-item><def-item><term>SIRI</term><def><p id="Par11">System inflammation response index</p></def></def-item><def-item><term>SII</term><def><p id="Par12">Systemic immune inflammation index</p></def></def-item><def-item><term>NCHS</term><def><p id="Par13">National Center for Health Statistics</p></def></def-item><def-item><term>MI</term><def><p id="Par14">Myocardial infarction</p></def></def-item><def-item><term>CHF</term><def><p id="Par15">Congestive heart failure </p></def></def-item><def-item><term>CHD </term><def><p id="Par16">Coronary heart disease</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par17">Glycated hemoglobin</p></def></def-item><def-item><term>BMI </term><def><p id="Par18">Body mass index</p></def></def-item><def-item><term>COVID-19</term><def><p id="Par19">Coronavirus disease 2019</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Run Wang and Ruoling Chen contributed equally to this work and share first authorship.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are thankful to the National Health and Nutrition Examination Survey (NHANES) for providing the database that enriched our research. Their valuable data contribution was a cornerstone in the development of our study.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>R.W. and Rl.C. conceived the study design and are responsible for the overall content. R.W. and XB.C. analyzed and interpreted the data. R.W. and WJ.T. acquired the data. R.W. prepared the manuscript. All authors approved the submitted and final versions.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the 2024 Bengbu Medical College Science and Technology Project (Grant no.2024byzd367), 2023 Hefei Third People&#8217;s Hospital Institutional-Level Scientific Research Project (Grant no. SYKY202303) and The Sixth Batch of Renowned Physician Studios in Hefei City.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The NHANES website hosts the datasets created and examined in this study: <ext-link ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/nhanes/default.aspx">https://wwwn.cdc.gov/nchs/nhanes/default.aspx</ext-link>.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">This study was conducted in accordance with the Declaration of Helsinki and approved by the relevant ethics committee. The protocols of NHANES were approved by the Institutional Review Board of the National Center for Health Statistics, CDC (<ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nhanes/about/erb.html?">https://www.cdc.gov/nchs/nhanes/about/erb.html?</ext-link>). NHANES has obtained written informed consent from all participants.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Consent to publish was given by each NHANES research participant.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990&#8211;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223&#8211;1249.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30752-2</pub-id><pub-id pub-id-type="pmcid">PMC7566194</pub-id><pub-id pub-id-type="pmid">33069327</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>CW</given-names></name><name name-style="western"><surname>Aday</surname><given-names>AW</given-names></name><name name-style="western"><surname>Almarzooq</surname><given-names>ZI</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>CAM</given-names></name><name name-style="western"><surname>Arora</surname><given-names>P</given-names></name><name name-style="western"><surname>Avery</surname><given-names>CL</given-names></name><name name-style="western"><surname>Baker-Smith</surname><given-names>CM</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Boehme</surname><given-names>AK</given-names></name><name name-style="western"><surname>Buxton</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association</article-title><source>Circulation</source><year>2023</year><volume>147</volume><issue>8</issue><fpage>e93</fpage><lpage>e621</lpage><pub-id pub-id-type="pmid">36695182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000001123</pub-id><pub-id pub-id-type="pmcid">PMC12135016</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93&#8211;621.<pub-id pub-id-type="pmid">36695182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000001123</pub-id><pub-id pub-id-type="pmcid">PMC12135016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">3. Henein MY, Vancheri S, Longo G, Vancheri F. The Role of Inflammation in Cardiovascular Disease. Int J Mol Sci. 2022;23(21):12906.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232112906</pub-id><pub-id pub-id-type="pmcid">PMC9658900</pub-id><pub-id pub-id-type="pmid">36361701</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruparelia</surname><given-names>N</given-names></name><name name-style="western"><surname>Chai</surname><given-names>JT</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>EA</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>RP</given-names></name></person-group><article-title>Inflammatory processes in cardiovascular disease: a route to targeted therapies</article-title><source>Nat Rev Cardiol</source><year>2017</year><volume>14</volume><issue>3</issue><fpage>133</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">27905474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrcardio.2016.185</pub-id><pub-id pub-id-type="pmcid">PMC5525550</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14(3):133&#8211;44.<pub-id pub-id-type="pmid">27905474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrcardio.2016.185</pub-id><pub-id pub-id-type="pmcid">PMC5525550</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goswami</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ranjan</surname><given-names>P</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>RK</given-names></name><name name-style="western"><surname>Verma</surname><given-names>SK</given-names></name></person-group><article-title>Management of inflammation in cardiovascular diseases</article-title><source>Pharmacol Res</source><year>2021</year><volume>173</volume><fpage>105912</fpage><pub-id pub-id-type="pmid">34562603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2021.105912</pub-id><pub-id pub-id-type="pmcid">PMC8541927</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Goswami SK, Ranjan P, Dutta RK, Verma SK. Management of inflammation in cardiovascular diseases. Pharmacol Res. 2021;173:105912.<pub-id pub-id-type="pmid">34562603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2021.105912</pub-id><pub-id pub-id-type="pmcid">PMC8541927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Sorriento D, Iaccarino G. Inflammation and Cardiovascular Diseases: The Most Recent Findings. Int J Mol Sci.&#160;2019;20(16):3879. <pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20163879</pub-id><pub-id pub-id-type="pmcid">PMC6719998</pub-id><pub-id pub-id-type="pmid">31395800</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#228;ck</surname><given-names>M</given-names></name><name name-style="western"><surname>Yurdagul</surname><given-names>A</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Tabas</surname><given-names>I</given-names></name><name name-style="western"><surname>&#214;&#246;rni</surname><given-names>K</given-names></name><name name-style="western"><surname>Kovanen</surname><given-names>PT</given-names></name></person-group><article-title>Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities</article-title><source>Nat Rev Cardiol</source><year>2019</year><volume>16</volume><issue>7</issue><fpage>389</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">30846875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-019-0169-2</pub-id><pub-id pub-id-type="pmcid">PMC6727648</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">B&#228;ck M, Yurdagul A Jr, Tabas I, &#214;&#246;rni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16(7):389&#8211;406.<pub-id pub-id-type="pmid">30846875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-019-0169-2</pub-id><pub-id pub-id-type="pmcid">PMC6727648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>P</given-names></name><name name-style="western"><surname>Ali</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Ghosheh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ley</surname><given-names>K</given-names></name></person-group><article-title>Opportunities for an atherosclerosis vaccine: From mice to humans</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><issue>28</issue><fpage>4495</fpage><lpage>4506</lpage><pub-id pub-id-type="pmid">31964554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.12.039</pub-id><pub-id pub-id-type="pmcid">PMC7939143</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Roy P, Ali AJ, Kobiyama K, Ghosheh Y, Ley K. Opportunities for an atherosclerosis vaccine: From mice to humans. Vaccine. 2020;38(28):4495&#8211;506.<pub-id pub-id-type="pmid">31964554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.12.039</pub-id><pub-id pub-id-type="pmcid">PMC7939143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Arb&#259;na&#537;i EM, Halmaciu I, Kaller R, Mure&#537;an AV, Arb&#259;na&#537;i EM, Suciu BA, Co&#537;arc&#259; CM, Cojocaru, II, Melinte RM, Russu E. Systemic Inflammatory Biomarkers and Chest CT Findings as Predictors of Acute Limb Ischemia Risk, Intensive Care Unit Admission, and Mortality in COVID-19 Patients. Diagnostics (Basel). 2022;12(10):2379.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics12102379</pub-id><pub-id pub-id-type="pmcid">PMC9600434</pub-id><pub-id pub-id-type="pmid">36292068</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Bao</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>The aggregate index of systemic inflammation (AISI): a novel predictor for hypertension</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1163900</fpage><pub-id pub-id-type="pmid">37265570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2023.1163900</pub-id><pub-id pub-id-type="pmcid">PMC10229810</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Xiu J, Lin X, Chen Q, Yu P, Lu J, Yang Y, Chen W, Bao K, Wang J, Zhu J, et al. The aggregate index of systemic inflammation (AISI): a novel predictor for hypertension. Front Cardiovasc Med. 2023;10:1163900.<pub-id pub-id-type="pmid">37265570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2023.1163900</pub-id><pub-id pub-id-type="pmcid">PMC10229810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>C</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D</given-names></name><name name-style="western"><surname>Dou</surname><given-names>K</given-names></name></person-group><article-title>Prognostic Value of Multiple Complete Blood Count-Derived Indices in Intermediate Coronary Lesions</article-title><source>Angiology</source><year>2025</year><volume>76</volume><issue>2</issue><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1177/00033197231198678</pub-id><pub-id pub-id-type="pmid">37646226</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yang Y, Song C, Jia L, Dong Q, Song W, Yin D, Dou K. Prognostic Value of Multiple Complete Blood Count-Derived Indices in Intermediate Coronary Lesions. Angiology. 2025;76(2):141&#8211;53. 10.1177/00033197231198678.<pub-id pub-id-type="pmid">37646226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00033197231198678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">12. Melinte RM, Arb&#259;na&#537;i EM, Blesneac A, Zolog DN, Kaller R, Mure&#537;an AV, Arb&#259;na&#537;i EM, Melinte IM, Niculescu R, Russu E. Inflammatory Biomarkers as Prognostic Factors of Acute Deep Vein Thrombosis Following the Total Knee Arthroplasty. Medicina (Kaunas). 2022,58(10):1502.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medicina58101502</pub-id><pub-id pub-id-type="pmcid">PMC9608310</pub-id><pub-id pub-id-type="pmid">36295662</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Shu</surname><given-names>M</given-names></name><name name-style="western"><surname>Xue</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: A cross-sectional study</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1100453</fpage><pub-id pub-id-type="pmid">36875480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1100453</pub-id><pub-id pub-id-type="pmcid">PMC9978802</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Song Y, Zhao Y, Shu Y, Zhang L, Cheng W, Wang L, Shu M, Xue B, Wang R, Feng Z, et al. Combination model of neutrophil to high-density lipoprotein ratio and system inflammation response index is more valuable for predicting peripheral arterial disease in type 2 diabetic patients: A cross-sectional study. Front Endocrinol (Lausanne). 2023;14:1100453.<pub-id pub-id-type="pmid">36875480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1100453</pub-id><pub-id pub-id-type="pmcid">PMC9978802</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HK</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Lu</surname><given-names>TY</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name></person-group><article-title>Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study</article-title><source>Cancer Cell Int</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>13</fpage><pub-id pub-id-type="pmid">36707809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-02856-3</pub-id><pub-id pub-id-type="pmcid">PMC9881346</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wang HK, Wei Q, Yang YL, Lu TY, Yan Y, Wang F. Clinical usefulness of the lymphocyte-to-monocyte ratio and aggregate index of systemic inflammation in patients with esophageal cancer: a retrospective cohort study. Cancer Cell Int. 2023;23(1):13.<pub-id pub-id-type="pmid">36707809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-023-02856-3</pub-id><pub-id pub-id-type="pmcid">PMC9881346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odutayo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gill</surname><given-names>P</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>S</given-names></name><name name-style="western"><surname>Akingbade</surname><given-names>A</given-names></name><name name-style="western"><surname>Hopewell</surname><given-names>S</given-names></name><name name-style="western"><surname>Tennankore</surname><given-names>K</given-names></name><name name-style="western"><surname>Hunn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Emdin</surname><given-names>CA</given-names></name></person-group><article-title>Income Disparities in Absolute Cardiovascular Risk and Cardiovascular Risk Factors in the United States, 1999&#8211;2014</article-title><source>JAMA Cardiol</source><year>2017</year><volume>2</volume><issue>7</issue><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">28593301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2017.1658</pub-id><pub-id pub-id-type="pmcid">PMC5710615</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Odutayo A, Gill P, Shepherd S, Akingbade A, Hopewell S, Tennankore K, Hunn BH, Emdin CA. Income Disparities in Absolute Cardiovascular Risk and Cardiovascular Risk Factors in the United States, 1999&#8211;2014. JAMA Cardiol. 2017;2(7):782&#8211;90.<pub-id pub-id-type="pmid">28593301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2017.1658</pub-id><pub-id pub-id-type="pmcid">PMC5710615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>JA</given-names></name></person-group><article-title>Dietary Guidelines for Americans, 2020&#8211;2025</article-title><source>Workplace Health Saf</source><year>2021</year><volume>69</volume><issue>8</issue><fpage>395</fpage><pub-id pub-id-type="pmid">34279148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/21650799211026980</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Phillips JA. Dietary Guidelines for Americans, 2020&#8211;2025. Workplace Health Saf. 2021;69(8):395.<pub-id pub-id-type="pmid">34279148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/21650799211026980</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eke</surname><given-names>PI</given-names></name><name name-style="western"><surname>Dye</surname><given-names>BA</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L</given-names></name><name name-style="western"><surname>Slade</surname><given-names>GD</given-names></name><name name-style="western"><surname>Thornton-Evans</surname><given-names>GO</given-names></name><name name-style="western"><surname>Borgnakke</surname><given-names>WS</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>GW</given-names></name><name name-style="western"><surname>Page</surname><given-names>RC</given-names></name><name name-style="western"><surname>Beck</surname><given-names>JD</given-names></name><name name-style="western"><surname>Genco</surname><given-names>RJ</given-names></name></person-group><article-title>Update on Prevalence of Periodontitis in Adults in the United States: NHANES 2009 to 2012</article-title><source>J Periodontol</source><year>2015</year><volume>86</volume><issue>5</issue><fpage>611</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">25688694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1902/jop.2015.140520</pub-id><pub-id pub-id-type="pmcid">PMC4460825</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS, Taylor GW, Page RC, Beck JD, Genco RJ. Update on Prevalence of Periodontitis in Adults in the United States: NHANES 2009 to 2012. J Periodontol. 2015;86(5):611&#8211;22.<pub-id pub-id-type="pmid">25688694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1902/jop.2015.140520</pub-id><pub-id pub-id-type="pmcid">PMC4460825</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahemuti</surname><given-names>N</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015&#8211;2020)</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><issue>5</issue><fpage>1177</fpage><pub-id pub-id-type="pmid">36904176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15051177</pub-id><pub-id pub-id-type="pmcid">PMC10004774</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Mahemuti N, Jing X, Zhang N, Liu C, Li C, Cui Z, Liu Y, Chen J. Association between Systemic Immunity-Inflammation Index and Hyperlipidemia: A Population-Based Study from the NHANES (2015&#8211;2020). Nutrients. 2023;15(5):1177.<pub-id pub-id-type="pmid">36904176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu15051177</pub-id><pub-id pub-id-type="pmcid">PMC10004774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation . 2002;106(25):3143&#8211;3421.<pub-id pub-id-type="pmid">12485966</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A</given-names></name><name name-style="western"><surname>Paliogiannis</surname><given-names>P</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name></person-group><article-title>Aggregate Index of Systemic Inflammation (AISI), Disease Severity, and Mortality in COVID-19: A Systematic Review and Meta-Analysis</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>14</issue><fpage>4584</fpage><pub-id pub-id-type="pmid">37510699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12144584</pub-id><pub-id pub-id-type="pmcid">PMC10381001</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zinellu A, Paliogiannis P, Mangoni AA. Aggregate Index of Systemic Inflammation (AISI), Disease Severity, and Mortality in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(14):4584.<pub-id pub-id-type="pmid">37510699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12144584</pub-id><pub-id pub-id-type="pmcid">PMC10381001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ercan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Evren &#214;ztop</surname><given-names>K</given-names></name><name name-style="western"><surname>P&#305;nar</surname><given-names>M</given-names></name><name name-style="western"><surname>Varim</surname><given-names>C</given-names></name><name name-style="western"><surname>Dheir</surname><given-names>H</given-names></name><name name-style="western"><surname>Karacaer</surname><given-names>C</given-names></name><name name-style="western"><surname>Yaylaci</surname><given-names>S</given-names></name><name name-style="western"><surname>Bilal Gen&#231;</surname><given-names>A</given-names></name><name name-style="western"><surname>&#199;eki&#231;</surname><given-names>D</given-names></name><name name-style="western"><surname>Nalbant</surname><given-names>A</given-names></name><etal/></person-group><article-title>The aggregate index of systemic inflammation may predict mortality in COVID-19 patients with chronic renal failure</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2023</year><volume>27</volume><issue>8</issue><fpage>3747</fpage><lpage>3752</lpage><pub-id pub-id-type="pmid">37140323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202304_32173</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ercan Z, Evren &#214;ztop K, P&#305;nar M, Varim C, Dheir H, Karacaer C, Yaylaci S, Bilal Gen&#231; A, &#199;eki&#231; D, Nalbant A, et al. The aggregate index of systemic inflammation may predict mortality in COVID-19 patients with chronic renal failure. Eur Rev Med Pharmacol Sci. 2023;27(8):3747&#8211;52.<pub-id pub-id-type="pmid">37140323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202304_32173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinellu</surname><given-names>A</given-names></name><name name-style="western"><surname>Collu</surname><given-names>C</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>M</given-names></name><name name-style="western"><surname>Paliogiannis</surname><given-names>P</given-names></name><name name-style="western"><surname>Mellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Zinellu</surname><given-names>E</given-names></name><name name-style="western"><surname>Traclet</surname><given-names>J</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>K</given-names></name><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name><name name-style="western"><surname>Carru</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><issue>18</issue><fpage>4134</fpage><pub-id pub-id-type="pmid">34575245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10184134</pub-id><pub-id pub-id-type="pmcid">PMC8466198</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, Traclet J, Ahmad K, Mangoni AA, Carru C, et al. The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. J Clin Med. 2021;10(18):4134.<pub-id pub-id-type="pmid">34575245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10184134</pub-id><pub-id pub-id-type="pmcid">PMC8466198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Aiyasiding</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HH</given-names></name><name name-style="western"><surname>Tang</surname><given-names>QZ</given-names></name></person-group><article-title>Neutrophil degranulation and myocardial infarction</article-title><source>Cell Commun Signal</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>50</fpage><pub-id pub-id-type="pmid">35410418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-022-00824-4</pub-id><pub-id pub-id-type="pmcid">PMC8996539</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zhang N, Aiyasiding X, Li WJ, Liao HH, Tang QZ. Neutrophil degranulation and myocardial infarction. Cell Commun Signal. 2022;20(1):50.<pub-id pub-id-type="pmid">35410418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-022-00824-4</pub-id><pub-id pub-id-type="pmcid">PMC8996539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonaventura</surname><given-names>A</given-names></name><name name-style="western"><surname>Vecchi&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Abbate</surname><given-names>A</given-names></name><name name-style="western"><surname>Montecucco</surname><given-names>F</given-names></name></person-group><article-title>Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>231</fpage><pub-id pub-id-type="pmid">31963447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9010231</pub-id><pub-id pub-id-type="pmcid">PMC7016588</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bonaventura A, Vecchi&#233; A, Abbate A, Montecucco F. Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update. Cells. 2020;9(1):231.<pub-id pub-id-type="pmid">31963447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9010231</pub-id><pub-id pub-id-type="pmcid">PMC7016588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamstein</surname><given-names>NH</given-names></name><name name-style="western"><surname>MacFadyen</surname><given-names>JG</given-names></name><name name-style="western"><surname>Rose</surname><given-names>LM</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Dey</surname><given-names>AK</given-names></name><name name-style="western"><surname>Libby</surname><given-names>P</given-names></name><name name-style="western"><surname>Tabas</surname><given-names>IA</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>NN</given-names></name><name name-style="western"><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>9</issue><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">33417682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa1034</pub-id><pub-id pub-id-type="pmcid">PMC7936519</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, Tabas IA, Mehta NN, Ridker PM. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021;42(9):896&#8211;903.<pub-id pub-id-type="pmid">33417682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa1034</pub-id><pub-id pub-id-type="pmcid">PMC7936519</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>AD</given-names></name><name name-style="western"><surname>Denaxas</surname><given-names>S</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>O</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hemingway</surname><given-names>H</given-names></name></person-group><article-title>Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>69</volume><issue>9</issue><fpage>1160</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">28254179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2016.12.022</pub-id><pub-id pub-id-type="pmcid">PMC5332591</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Shah AD, Denaxas S, Nicholas O, Hingorani AD, Hemingway H. Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study. J Am Coll Cardiol. 2017;69(9):1160&#8211;9.<pub-id pub-id-type="pmid">28254179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2016.12.022</pub-id><pub-id pub-id-type="pmcid">PMC5332591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Ruiz</surname><given-names>I</given-names></name></person-group><article-title>Neutrophil-driven SMC death destabilizes atherosclerotic plaques</article-title><source>Nat Rev Cardiol</source><year>2019</year><volume>16</volume><issue>8</issue><fpage>455</fpage><pub-id pub-id-type="pmid">31101895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-019-0214-1</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Fern&#225;ndez-Ruiz I. Neutrophil-driven SMC death destabilizes atherosclerotic plaques. Nat Rev Cardiol. 2019;16(8):455.<pub-id pub-id-type="pmid">31101895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-019-0214-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moroni</surname><given-names>F</given-names></name><name name-style="western"><surname>Ammirati</surname><given-names>E</given-names></name><name name-style="western"><surname>Norata</surname><given-names>GD</given-names></name><name name-style="western"><surname>Magnoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Camici</surname><given-names>PG</given-names></name></person-group><article-title>The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis</article-title><source>Mediators Inflamm</source><year>2019</year><volume>2019</volume><fpage>7434376</fpage><pub-id pub-id-type="pmid">31089324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/7434376</pub-id><pub-id pub-id-type="pmcid">PMC6476044</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. Mediators Inflamm. 2019;2019:7434376.<pub-id pub-id-type="pmid">31089324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/7434376</pub-id><pub-id pub-id-type="pmcid">PMC6476044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>SD</given-names></name><name name-style="western"><surname>Mussbacher</surname><given-names>M</given-names></name></person-group><article-title>Galkina EV Functional Role of B Cells in Atherosclerosis</article-title><source>Cells</source><year>2021</year><volume>10</volume><issue>2</issue><fpage>270</fpage><pub-id pub-id-type="pmid">33572939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10020270</pub-id><pub-id pub-id-type="pmcid">PMC7911276</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ma SD, Mussbacher M. Galkina EV Functional Role of B Cells in Atherosclerosis. Cells. 2021;10(2):270.<pub-id pub-id-type="pmid">33572939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10020270</pub-id><pub-id pub-id-type="pmcid">PMC7911276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ketelhuth</surname><given-names>DF</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Adaptive Response of T and B Cells in Atherosclerosis</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><issue>4</issue><fpage>668</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">26892965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.115.306427</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ketelhuth DF, Hansson GK. Adaptive Response of T and B Cells in Atherosclerosis. Circ Res. 2016;118(4):668&#8211;78.<pub-id pub-id-type="pmid">26892965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.115.306427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Hundelshausen</surname><given-names>P</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name></person-group><article-title>Platelets as immune cells: bridging inflammation and cardiovascular disease</article-title><source>Circ Res</source><year>2007</year><volume>100</volume><issue>1</issue><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">17204662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.RES.0000252802.25497.b7</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100(1):27&#8211;40.<pub-id pub-id-type="pmid">17204662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.RES.0000252802.25497.b7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stark</surname><given-names>K</given-names></name><name name-style="western"><surname>Massberg</surname><given-names>S</given-names></name></person-group><article-title>Interplay between inflammation and thrombosis in cardiovascular pathology</article-title><source>Nat Rev Cardiol</source><year>2021</year><volume>18</volume><issue>9</issue><fpage>666</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">33958774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-021-00552-1</pub-id><pub-id pub-id-type="pmcid">PMC8100938</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18(9):666&#8211;82.<pub-id pub-id-type="pmid">33958774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-021-00552-1</pub-id><pub-id pub-id-type="pmcid">PMC8100938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sardu</surname><given-names>C</given-names></name><name name-style="western"><surname>Paolisso</surname><given-names>G</given-names></name><name name-style="western"><surname>Marfella</surname><given-names>R</given-names></name></person-group><article-title>Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets</article-title><source>Curr Pharm Des</source><year>2020</year><volume>26</volume><issue>22</issue><fpage>2565</fpage><lpage>2573</lpage><pub-id pub-id-type="pmid">32053065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612826666200213123029</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Sardu C, Paolisso G, Marfella R. Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets. Curr Pharm Des. 2020;26(22):2565&#8211;73.<pub-id pub-id-type="pmid">32053065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1381612826666200213123029</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>